Nevertheless, motixafortide + G-CSF preferentially mobilized a higher proportion of the transcriptionally primitive HSC1 population (31.42%) relative to either plerixafor + G-CSF (17.36%) or placebo + G-CSF (22.77%) in patients with MM. Here, CSF3 is linked to Miyoshi myopathy.